SLNCF

distress 5/10 · elevated risk

$1.500%today-43% from 52w high

silence-therapeutics.com88 employeesFounded 1994London, United KingdomBiotechnology

Lead: polycythemia vera

Revenue

pre-revenue

Liquidity

$70M

Runway

1.1 yrs

Shares 1y

Price & events

+0.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.0%

-31.8%

-36.4%

+0.0%

-6.3%

-80.3%

-82.4%

-78.6%

All

Overview

Market Cap: $212.56M
Volume: 0
52 Week Range: $1.06 – $2.63
Total Shares: 141.70M
Float Shares: 82.38M
% Held by Insiders: 8.75%
% Held by Institutions: 0.00%
Beta: 1.38

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 9

in 2026Guided 40%conferencedata presentationsecondaryPhase 1SLN312 · Phase 1 data presentations at medical and research congressesSEC 8-K
third quarter of 2026Guided 70%readoutPhase 2divesiran · Initial topline results from SANRECO Phase 2 study anticipated.SEC 8-K
second quarter of 2026conferencedata presentationsecondarySLN098 · Additional preclinical data for INHBE programSEC 8-K
second quarter of 2026conferencedata presentationsecondarySLN365 · Additional preclinical data for GPR146 programSEC 8-K
2026-03-05partnershipSLN312 · Silence re-gains global rights to SLN312 from AstraZeneca after Phase 1.SEC 8-K
2026-03-04withdrawalSLN312 · AstraZeneca notified Silence that they will not pursue further development of SLN312 beyond Phase 1.SEC 8-K
2025conferencedata presentationsecondaryPhase 1divesiran · Data presentations from the SANRECO Phase 1 study anticipated at medical congresses.SEC 8-K
second half of 2025trial initiationsecondaryPhase 1SLN548 · Phase 1 study planned.SEC 8-K
by year-end 2025enrollment completesecondaryPhase 2divesiran · Full enrollment anticipated in the SANRECO Phase 2 study.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 141,703,840 · 1 offerings/1y · 0 PIPEs

2026-05-27424B5offering
2026-05-27EFFECTshelf_effective
2026-05-188-Kmaterial_agreement
2026-05-18S-3shelf_registration
2024-11-14SC 13G/Astrategic_stake
2024-11-14SC 13G/Astrategic_stake
2024-11-12SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.